Lannett Company, Inc. (LCI) |
|
1.59 -0.07 (-4.22%)
|
03-24 15:59 |
|
Open: |
1.71 |
Pre. Close: |
1.66 |
|
High:
|
1.665 |
Low:
|
1.56 |
|
Volume:
|
26,024 |
Market Cap:
|
17(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:27:37 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 2.53 One year: 2.97 |
| Support: |
Support1: 1.55 Support2: 1.29 |
| Resistance: |
Resistance1: 2.17 Resistance2: 2.54 |
| Pivot: |
1.81 |
| Moving Average: |
MA(5): 1.67 MA(20): 1.89
MA(100): 2.28 MA(250): 2.25 |
| MACD: |
MACD(12,26): -0.2 Signal(9): -0.2 |
| Stochastic oscillator: |
%K(14,3): 12.7 %D(3): 15.3  |
| RSI: |
RSI(14): 30.7 |
| 52-week: |
High: 3.72 Low: 0.49 |
| Average Vol(K): |
3-Month: 76 (K) 10-Days: 61 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LCI ] has closed above bottom band by 16.8%. Bollinger Bands are 27.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
1.71 - 1.72 |
1.72 - 1.73 |
|
Low:
|
1.54 - 1.55 |
1.55 - 1.56 |
|
Close:
|
1.57 - 1.59 |
1.59 - 1.6 |
|
Company Description |
|
Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral and extended release, topical, liquid, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, nasal, patch, foam, buccal, sublingual, suspensions, soft gel, injectable, and oral dosages. It also provides its products for various medical indications, such as analgesic, anti-psychosis, cardiovascular, central nervous system, endocrinology, gastrointestinal, infectious disease, migraine, respiratory/allergy/cough/cold, urinary, and others medical indications. The company's primary products include Levothyroxine Sodium tablets, Fluphenazine tablets, Posaconazole DR tablets, Verapamil SR tablets, Methylphenidate CD capsules, Omeprazole capsules, Pantoprazole Sodium DR tablets, Sumatriptan Nasal spray, Metolazone tablets, Amphetamine IR Tablets, Methylphenidate Hydrochloride ER stimulants, as well as cocaine hydrochloride solution. It sells its pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical companies, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with Summit Bioscience LLC, HEC Group of companies, Dexcel Pharma, Elite Pharmaceuticals, RivoPharm, and various other companies. Lannett Company, Inc. was incorporated in 1942 and is headquartered in Trevose, Pennsylvania. |
Headline News |
Tue, 21 Feb 2023
Should You Hold Lannett Company, Inc. (LCI) Stock Tuesday Morning? - InvestorsObserver
Tue, 07 Feb 2023
Recent uptick might appease Lannett Company, Inc. (NYSE:LCI) institutional owners after losing 26% over the past year - Yahoo Finance
Wed, 01 Feb 2023
LANNETT REPORTS IMPROVED FISCAL 2023 SECOND QUARTER FINANCIAL RESULTS; RAISES FULL-YEAR GUIDANCE - Yahoo Finance
Wed, 25 Jan 2023
LANNETT TO REPORT FISCAL 2023 SECOND-QUARTER FINANCIAL RESULTS, HOST CONFERENCE CALL ON WEDNESDAY, FEBRUARY 1 - Yahoo Finance
Wed, 25 Jan 2023
LANNETT ANNOUNCES 1 FOR 4 REVERSE STOCK SPLIT - PR Newswire
Mon, 07 Nov 2022
LANNETT ANNOUNCES PATENT LICENSES FOR THE PEN ... - PR Newswire
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Underperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
11 (M) |
| Shares Float |
8 (M) |
|
% Held by Insiders
|
14.2 (%) |
|
% Held by Institutions
|
37.8 (%) |
|
Shares Short
|
1,050 (K) |
|
Shares Short P.Month
|
994 (K) |
Stock Financials |
|
EPS
|
-17.55 |
|
EPS Est Next Qtl
|
0.66 |
|
EPS Est This Year
|
2.59 |
|
EPS Est Next Year
|
2.75 |
|
Book Value (p.s.)
|
-30.29 |
|
Profit Margin (%)
|
-62.5 |
|
Operating Margin (%)
|
-20.9 |
|
Return on Assets (ttm)
|
-7.9 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
-6.5 |
|
Gross Profit (p.s.)
|
4.28 |
|
Sales Per Share
|
28.64 |
|
EBITDA (p.s.)
|
-3.4 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-52 (M) |
|
Levered Free Cash Flow
|
19 (M) |
Stock Valuations |
|
PE Ratio
|
-0.1 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
-0.06 |
|
Price to Sales
|
0.05 |
|
Price to Cash Flow
|
-0.34 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
